High dose therapy with allogeneic or autologous stem celltransplantation as well as additional supportive measures havebrought important advances in the therapy of malignantdiseases allogeneic and especially autologous peripheral blood stem cellgrafting as opposed to allogeneic bone marrow transplantation is asubject of intensive research. To determine the outcome of high dose therapy with autologous hematopoietic stem cell transplantation hsct in patients with primary systemic amyloidosis reported to the center for international blood and marrow transplant research cibmtr we compared overall survival in patients who underwent transplantation in 2000 2001 with overall . High dose therapy with supporting autologous stem cell transplantation remains a controversial treatment for cancer in multiple myeloma first line regimens incorporating high dose therapy yield . Therefore patients with dialysis dependent renal failure are frequently considered unfit for high dose therapy hdt and autologous hematopoietic stem cell transplantation auto hct the existing data suggest that melphalan dose reduction to 140 mg m 2 is less toxic than 200 mg m 2 . Intensive induction chemotherapy followed by early high dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic t cell lymphoma a single institution experience
How it works:
1. Register a Free 1 month Trial Account.
2. Download as many books as you like ( Personal use )
3. No Commitment. Cancel anytime.
4. Join Over 100.000 Happy Readers.
5. That's it. What you waiting for? Sign Up and Get Your Books.